Janumet™ (MK-0431A) combines two OADs with complementary mechanisms of action to improve glycemic control, sitagliptin and metformin. The tablet was designed in order to be bioequivalent to ...

Insulin is needed less frequently and HbA1c is lowered more robustly when adults with type 2 diabetes do not delay combination therapy but begin treatment by taking sitagliptin and metformin together, ...

In Korean adults with type 2 diabetes, combination sitagliptin and metformin as first-line therapy showed a greater improvement in glycemic control and fasting plasma glucose at 30 weeks vs.

Sitagliptin (trade names: Januvia and Xelevia) is approved for certain adults with type 2 diabetes mellitus whose blood-glucose levels are inadequately controlled by diet and exercise alone. The fixed ...

MUNICH -- For type 2 diabetes patients uncontrolled on metformin and sitagliptin (Januvia), adding the novel sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin improved glycemic levels, a ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- New data were presented at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions from a study comparing ...

Merck and Pfizer announced at the American Diabetes Association 77th Scientific Sessions, San Diego, CA, that two Phase 3 studies evaluating ertugliflozin in adults with type 2 diabetes met their ...

Bristol-Myers Squibb and AstraZeneca announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin demonstrated significant reductions in HbA1C compared with ...

In the USA, patients with T2DM are treated with sitagliptin as monotherapy as an adjunct to diet and exercise, or in combination with metformin or TZD. Recently, the US FDA approved Janumet as initial ...

New data presented at the American Diabetes Association 70 th Annual Scientific Sessions WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- New data were presented at the American Diabetes Association (ADA) ...